Earnings Feed
Start Free
Home/Filings/3/0001209191-20-043551
3//SEC Filing

COLUMN GROUP GP, LP 3

Accession 0001209191-20-043551

CIK 0001549595other
View on SEC.govCompany Profile

Filed

Jul 22, 8:00 PM ET

Accepted

Jul 23, 7:26 PM ET

Size

28.2 KB

Accession

0001209191-20-043551

Insider Transaction Report

Form 3
Period: 2020-07-23
Nurix Therapeutics, Inc.NRIX
COLUMN GROUP L P
10% Owner
Holdings

  • Series A-2 Preferred Stock

    Exercise: $0.00→ Common Stock (875,000 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,989,000 underlying)

  • Director Stock Option (Right to Buy)

    (indirect: See Footnote)
    Exercise: $9.57Exp: 2030-05-27→ Common Stock (18,333 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,836,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Common Stock

    83,333

  • Series A-1 Preferred Stock

    Exercise: $0.00→ Common Stock (600,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)
COLUMN GROUP GP, LP
10% OwnerOther
Holdings

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,989,000 underlying)

  • Series A-1 Preferred Stock

    Exercise: $0.00→ Common Stock (600,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Director Stock Option (Right to Buy)

    (indirect: See Footnote)
    Exercise: $9.57Exp: 2030-05-27→ Common Stock (18,333 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,836,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Common Stock

    83,333

  • Series A-2 Preferred Stock

    Exercise: $0.00→ Common Stock (875,000 underlying)
Column Group II GP, LP
10% OwnerOther
Holdings

  • Series A-1 Preferred Stock

    Exercise: $0.00→ Common Stock (600,000 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,989,000 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,836,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Common Stock

    83,333

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Director Stock Option (Right to Buy)

    (indirect: See Footnote)
    Exercise: $9.57Exp: 2030-05-27→ Common Stock (18,333 underlying)

  • Series A-2 Preferred Stock

    Exercise: $0.00→ Common Stock (875,000 underlying)
Ponoi II Management, LLC
10% OwnerOther
Holdings

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Series A-2 Preferred Stock

    Exercise: $0.00→ Common Stock (875,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Director Stock Option (Right to Buy)

    (indirect: See Footnote)
    Exercise: $9.57Exp: 2030-05-27→ Common Stock (18,333 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,989,000 underlying)

  • Common Stock

    83,333

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,836,000 underlying)

  • Series A-1 Preferred Stock

    Exercise: $0.00→ Common Stock (600,000 underlying)
Kutzkey Tim
10% OwnerOther
Holdings

  • Series A-2 Preferred Stock

    Exercise: $0.00→ Common Stock (875,000 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,989,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Common Stock

    83,333

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,836,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Series A-1 Preferred Stock

    Exercise: $0.00→ Common Stock (600,000 underlying)

  • Director Stock Option (Right to Buy)

    (indirect: See Footnote)
    Exercise: $9.57Exp: 2030-05-27→ Common Stock (18,333 underlying)
GOEDDEL DAVID V
10% OwnerOther
Holdings

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,989,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Director Stock Option (Right to Buy)

    (indirect: See Footnote)
    Exercise: $9.57Exp: 2030-05-27→ Common Stock (18,333 underlying)

  • Common Stock

    83,333

  • Series A-1 Preferred Stock

    Exercise: $0.00→ Common Stock (600,000 underlying)

  • Series A-2 Preferred Stock

    Exercise: $0.00→ Common Stock (875,000 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,836,000 underlying)
COLUMN GROUP II, LP
10% Owner
Holdings

  • Series A-1 Preferred Stock

    Exercise: $0.00→ Common Stock (600,000 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,836,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Series A-2 Preferred Stock

    Exercise: $0.00→ Common Stock (875,000 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,989,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Common Stock

    83,333

  • Director Stock Option (Right to Buy)

    (indirect: See Footnote)
    Exercise: $9.57Exp: 2030-05-27→ Common Stock (18,333 underlying)
PONOI CAPITAL, LP
10% Owner
Holdings

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,836,000 underlying)

  • Series A-1 Preferred Stock

    Exercise: $0.00→ Common Stock (600,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Common Stock

    83,333

  • Series A-2 Preferred Stock

    Exercise: $0.00→ Common Stock (875,000 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,989,000 underlying)

  • Director Stock Option (Right to Buy)

    (indirect: See Footnote)
    Exercise: $9.57Exp: 2030-05-27→ Common Stock (18,333 underlying)
Ponoi Management, LLC
10% OwnerOther
Holdings

  • Series A-1 Preferred Stock

    Exercise: $0.00→ Common Stock (600,000 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,836,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Common Stock

    83,333

  • Series A-2 Preferred Stock

    Exercise: $0.00→ Common Stock (875,000 underlying)

  • Director Stock Option (Right to Buy)

    (indirect: See Footnote)
    Exercise: $9.57Exp: 2030-05-27→ Common Stock (18,333 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,989,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)
Ponoi Capital II, LP
10% Owner
Holdings

  • Series A-1 Preferred Stock

    Exercise: $0.00→ Common Stock (600,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Common Stock

    83,333

  • Series A-2 Preferred Stock

    Exercise: $0.00→ Common Stock (875,000 underlying)

  • Series D Preferred Stock

    Exercise: $0.00→ Common Stock (686,274 underlying)

  • Director Stock Option (Right to Buy)

    (indirect: See Footnote)
    Exercise: $9.57Exp: 2030-05-27→ Common Stock (18,333 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,836,000 underlying)

  • Series B Preferred Stock

    Exercise: $0.00→ Common Stock (1,989,000 underlying)
Footnotes (7)
  • [F1]The number of shares reflects a 1-for-3 reverse stock split of the Issuer's common stock and preferred stock which became effective July 17, 2020. Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock will automatically convert into 1 share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date.
  • [F2]The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
  • [F3]The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
  • [F4]The securities are directly held by Ponoi Capital, LP ("Ponoi LP"), and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
  • [F5]The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"), and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
  • [F6]The stock option vests as to 1/48 of the total shares monthly beginning May 28, 2020 until the option is fully vested on April 28, 2024, subject to Leon Chen's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares subject to the Issuer's right or repurchase.
  • [F7]The stock option is held directly by Leon Chen, a director of the Issuer who is a partner of The Column Group which invests through TCG II LP, Ponoi LP and Ponoi II LP (collectively, the "Funds") among other entities. Under the partnership agreements of the Funds, Mr. Chen is deemed to hold the stock option for the economic benefit of the Funds. The reporting persons may be deemed indirect beneficial owners of the stock option. The reporting persons disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein.

Documents

1 file

Issuer

Nurix Therapeutics, Inc.

CIK 0001549595

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001614627

Filing Metadata

Form type
3
Filed
Jul 22, 8:00 PM ET
Accepted
Jul 23, 7:26 PM ET
Size
28.2 KB
View on SEC.gov